Hemophilia A

The explorer8 56-week analysis found sustained low bleeding rates with daily concizumab in males ≥12 years with hemophilia A or B without inhibitors.

A phase 3 BASIS analysis examined the use of factor replacement therapy for breakthrough bleeds and the perioperative management of minor and dental procedures among patients receiving marstacimab...

A phase 3 trial evaluated weekly marstacimab prophylaxis in adolescents and adults with hemophilia A or B with inhibitors.